Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO, President & Director Susan Horvath - VP, Finance, CFO, Secretary & Treasurer Conference Call Participants Robin Garner - Craig-Hallum Charles Butler - ROTH Capital Partners Operator Greetings, and welcome to Panbela Therapeutics' Second Quarter 2021 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0543922 (Sta ...

Panbela Therapeutics Inc. (OTCQB:PBLA) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Robin Garner - Craig-Hallum Operator Greetings and welcome to Panbela Therapeutics First Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39468 PANBELA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction (IRS Employer of incorpora ...